Regulatory

Feb 02, 2015
BioPharm International
FDA says it is “weighing the appropriate regulatory approach” to handle the tasks outlined by President Obama’s new Precision Medicine Initiative.
Feb 02, 2015
BioPharm International
The 2016 White House Budget proposes a change to the data exclusivity period for biologics and the authority to influence drug pricing.
Jan 30, 2015
BioPharm International
The development of intellectual property standards for biological products is a point of conflict as negotiations on the Trans-Pacific Partnership continue.
Jan 21, 2015
BioPharm International
Cosentyx (secukinumab) is the first IL-17A inhibitor for moderate-to-severe plaque psoriasis patients.
Jan 09, 2015
By BioPharm International Editors
A guidance document adds a four-month grace period.
Jan 09, 2015
Pharmaceutical Executive
Transparency, quality, collaboration key to filling pipelines, gaining reimbursement.
Jan 07, 2015
BioPharm International
An FDA panel unanimously recommended the agency approve EP2006, Sandoz’s biosimilar for filgrastim.
Dec 30, 2014
BioPharm International
By BioPharm International Editors
Hospira issued a voluntary worldwide recall due to confirmed subpotency and elevated impurity levels.
Dec 29, 2014
BioPharm International
By BioPharm International Editors
Entrectinib has received FDA’s orphan drug and rare pediatric disease designations for the treatment of neuroblastoma.
Dec 29, 2014
BioPharm International
By BioPharm International Editors
When used in combination with chlorambucil to treat chronic lymphocytic leukemia, Gazyva was found to be more effective than Rituxan.
native1_300x100
lorem ipsum